Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors from the central anxious method, conolidine modulates alternate molecular targets. A Science Innovations review identified that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://colettec722qjr8.blogscribble.com/profile